Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.

about

Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years

P2860

Q58795590-A9D0FD96-4B62-4E6C-B668-7FC7E828E0D7

P2860

Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.

Item

http://www.wikidata.org/entity/Q40687385

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Evaluation of an alternative e ...... t of gram-negative infections.

@en

type

Item

label

Evaluation of an alternative e ...... t of gram-negative infections.

@en

prefLabel

Evaluation of an alternative e ...... t of gram-negative infections.

@en

P1476

Evaluation of an alternative e ...... t of gram-negative infections.

@en

P2093

Erin M Winstead

http://www.w3.org/2001/XMLSchema#string

Joseph E Mueller

http://www.w3.org/2001/XMLSchema#string

Patrick D Ratliff

http://www.w3.org/2001/XMLSchema#string

William R Judd

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection

Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.

Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections

Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens.

The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.

Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.

A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.

Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.

Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.

P2888

s11096-016-0334-1

P304

1087-1093

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11096-016-0334-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ryan P Hickson

P577

2016-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27333796

http://www.w3.org/2001/XMLSchema#string

P921

Gram-negative bacteria

Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.

about

P2860

P2860

Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921